Genetic and Environment Influences on Expression of CVD Endophenotypes

$428,626P01FY2010HLNIH

Duke University, Durham NC

Investigators

Linked publications & trials

Paper 36461124 Paper 36136372 Paper 34610283 Paper 34470472 Paper 33462762 Paper 33288813 Paper 33077726 Paper 32792077 Paper 32179014 Paper 31714099 Paper 31642367 Paper 31002714 Paper 30882060 Paper 30771861 Paper 30349010 Paper 30333852 Paper 30188382 Paper 30041705 Paper 30008672 Paper 29191927 Paper 28760212 Paper 28267464 Paper 28249185 Paper 27649842 Paper 27082954 Paper 27004143 Paper 26938215 Paper 26803432 Paper 26214097 Paper 26202568 Paper 26147517 Paper 25807578 Paper 25564228 Paper 25514629 Paper 25497241 Paper 25457638 Paper 25271088 Paper 24933014 Paper 24806470 Paper 24660131 Paper 24634805 Paper 24386118 Paper 24163384 Paper 24011223 Paper 23936524 Paper 23927505 Paper 23726513 Paper 23695483 Paper 23550961 Paper 23458662 Paper 23435269 Paper 23299546 Paper 23231831 Paper 23223800 Paper 23144529 Paper 23140671 Paper 22659377 Paper 22545979 Paper 22283370 Paper 21976277 Paper 21967853 Paper 21778150 Paper 21730296 Paper 21364197 Paper 21357800 Paper 21283811 Paper 21141295 Paper 21098453 Paper 20635234 Paper 20595415 Paper 20467002 Paper 20300086 Paper 20190126 Paper 20178176 Paper 20100995 Paper 20100884 Paper 20012811 Paper 19800635 Paper 19561162 Paper 19553288 Paper 19539818 Paper 19515993 Paper 19470128 Paper 19455150 Paper 19181735 Paper 18661222 Paper 18639608 Paper 18467474 Paper 18417268 Paper 18400684 Paper 18227761 Paper 18158371 Paper 18020838 Paper 17955359 Paper 17766685 Paper 17716037 Paper 17630268 Paper 17626899 Paper 17585061 Paper 17510289

Abstract

The overarching objective of this Project is to identify genetic variants and environmental factors that act, whether interactively or Independently (main effects), to influence the expression of a wide range of psychosocial, behavioral and biological characteristics [CVD and Type 2 Diabetes (T2D) endophenotypes] that increase the risk of developing CVD and T2D among healthy persons as well as increase the risk of adverse clinical events in persons in whom CVD is already manifest. To achieve this objective we shall use use three samples - PPG-1 (N=165), Caregiver (170 caregivers of a relative with Alzheimer's Disease, 170 controls) and PPG-2 (644 from 400 families);with a total N of 1000+/- - in which we have extensive data re a broad range of T2D and CVD endophenotypes to identify promising genetic variants (using both candidate genes and GWAS-derived SNPs) that are associated with these predisease endophenotypes. A major thrust of our work on this Project will be to increase our confidence in the reality of these geneendo phenotype associations by replicating them, both within the three samples used by Project 1 and in the large healthy and clinical CAD samples being studied in Projects 2 and 3. A third aim will be to work closely with Projects 2 and 3 to complete the tranlational process, by showing that the genetic variants found associated in Project 1 with T2D and CVD endophenotypes are also associated in those Projects'samples with both the prevalence and incidence of CVD and T2D and clinical course.

View original record on NIH RePORTER →